U.S. Markets open in 37 mins

Allena Pharmaceuticals, Inc. (ALNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9050-0.0650 (-6.70%)
At close: 4:00PM EDT
0.9280 +0.02 (2.54%)
Pre-Market: 08:12AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9700
Open0.9500
Bid0.0000 x 800
Ask0.9481 x 1100
Day's Range0.9050 - 0.9885
52 Week Range0.7500 - 2.7800
Volume1,114,897
Avg. Volume2,816,487
Market Cap52.21M
Beta (5Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-0.9210
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.13
  • GlobeNewswire

    Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference

    NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will virtually participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021. Louis Brenner, M.D., Allena’s

  • GlobeNewswire

    Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

    ALLN-346 well-tolerated in recently completed Phase 1b study; first patients dosed in Phase 2a program for gout and chronic kidney disease; initial data expected in Q4 2021June KOL webinar highlighted the unmet need in gout and potential for ALLN-346Updated plan and timing for first interim analysis of Phase 3 URIROX-2 clinical trial of reloxaliase announced in July Registered direct offering completed in July with gross proceeds of $28.0 million NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) --

  • GlobeNewswire

    Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

    NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12th Annual Wedbush PacGrow Healthcare Conference on August 10th – August 11th, 2021. Louis Brenner, M.D., Allena’s President and Chief E